ANTICUERPOS MONOCLONALES CONTRA EL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO (EGFR) PARA USARSE EN EL TRATAMIENTO DE PACIENTES DIAGNOSTICADOS CON ADENOCARCINOMA DUCTAL PANCREÁTICO.
摘要The present disclosure relates to the field of immunotherapy of cancer, in particular pancreatic ductal adenocarcinoma (PDAC). Means and methods for treatment of a population of PDAC patients suffering from PDAC tumours which express wild-type KRAS, HRAS or NRAS are disclosed. The claimed antibody is Nimotuzumab. The pancreatic cancer preferably does not contain KRAS mutations at position 12, 16, 61, 154.
更多相关知识
- 浏览0
- 被引0
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



